Methotrexate use in systemic lupus erythematosus

Lupus

Volumn 6, Issue 4, 1997, Pages 385-389

  Kipen, Y ^a   Littlejohn, G O ^a   Morand, E F ^a  

^a MONASH MEDICAL CENTRE   (Australia)

Author keywords

Drug treatment; Methotrexate; Systemic lupus erythematosus

Indexed keywords

METHOTREXATE; STEROID;

ADULT; AGED; ARTHRITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG USE; FEMALE; HUMAN; MOUTH ULCER; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0030996043     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/096120339700600407     Document Type: Article

References (31)

1. Austin HA et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
2. Schnabel A, Gross WL. Low dose methotrexate in rheumatic diseases-efficacy, side effects, and risk factors for side effects. Sem Arthritis Rheum 1994; 23: 310-327.
3. Morand EF, McCloud PM, Littlejohn GO. Life table analysis of 879 treatment episodes with slow-acting anti-rheumatic drugs in community rheumatology practice. J Rheumatol 1992; 19: 704-708.
4. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 994-1002.
5. Williams HJ et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1985; 28: 721-730.
6. Weinblatt ME et al. Long term prospective study of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 129-137.
7. Andersen PA et al. Weekly pulse methotrexate in rheumatoid arthritis. Ann Rheum Dis 1985; 103: 489-496.
8. Kremer JM, Phelps CT. Long term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 138-145.
9. Fiechtner JJ, Miller DR, Starkebaum G. Reversal of neutropenia with methotrexate treatment in patients with felty's syndrome. Arthritis Rheum 1989; 32: 194-201.
10. Espinoza LR et al. Psoriatic arthritis: clinical response and side effects to methotrexate therapy. J Rheumatol 1992; 19: 872-877.
11. Sneller MC et al. An analysis of forty-two wegener' granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995; 38: 608-613.
12. Van Den Hoogen FHJ et al. Low dose methotrexate treatment in systemic sclerosis (letter). J Rheumatol 1991; 18: 1763-1764.
13. Davidson JR, Graziano FM, Rothenberg RJ. Methotrexate therapy for systemic lupus erythematosus (letter). Arthritis Rheum 1987; 30: 1195-1196.
14. Rothenberg RJ et al. The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum 1988; 31: 612-615.
15. Wilke WS et al. Methotrexate for systemic lupus erythematosus: A retrospective analysis of 17 unselected cases. Clin Exp Rheumatol 1991; 9: 581-587.
16. Abud-Medoza C, Sturbaum AK, Vazquez-Compean R, Gonzalez-Amaro. Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol 1993; 20: 731-733.
17. Walz LeBlanc BAE, Dagenais P, Urowitz MB, Gladman DD. Methotrexate in systemic lupus erythematosus. J Rheumatol 1994; 21: 836-838.
18. Wilson K, Abeles M. A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 1994; 21: 1674-1677.
19. Hawley DJ, Wolfe F. Are the results of controlled clinical trials and observational studies of second line therapy in rheumatoid arthritis valid and generalizable as measures of rheumatoid arthritis outcome: Analysis of 122 studies. J Rheumatol 1991; 18: 1008-1014.
20. Morand EF, McCloud PI, Littlejohn GO. Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 1992; 51: 1318-1321.
21. Tan EM et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277.
22. Gladman D et al. Systemic lupus international collaborative clinics development of a damage index in systemic lupus erythematosus. J Rheumatol 1992; 19: 1820-1821.
23. Jolivet J et al. The pharmacology and clinical use of methotrexate. N Eng J Med 1983; 309: 1094-1114.
24. Olsen NJ, Callahan LF, Diucas T. Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1987; 30: 481-488.
25. Olsen NJ, Murray LM. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989; 32: 378-385.
26. Chang DM, Bapiste P, Schur PH. The effect of antirheumatic drugs on interleukin 1 activity and IL-1 and IL-1 inhibitor production by human monocytes. J Rheumatol 1990; 17: 1148-1157.
27. Barrera P et al. Circulating soluble tumour necrosis factor receptors, interleukin-2 receptors, tumour necrosis factor α, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 1993; 36:
28. Segal R, Dayan N, Zinger H, Mozes E. Methotrexate treatment in murine experimental systemic lupus erythematosus; clinical benefits associated with cytokine manipulation. Clin Exp Immunol 1995; 101: 66-72;
29. Weinblatt ME et al. Arthritis Rheum 1988; 31: 167-175;
30. Miescher PA, Riethmuller D. Diagnosis and treatment of systemic lupus erythematosus. Sem Haematol 1965; 2: 1-28.
31. Dubois EL Management of discoid and systemic lupus erythematosus, Lupus Erythematosus. In: Dubois EL (ed). A review of the Current Status of Discoid and Systemic Lupus Erythematosus and Their Variants. 2nd end. University of Southern California Press: Los Angeles, 1974; pp 537-612.